The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study

The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study

ABSTRACT Radiographic vertebral fractures (VFxs) are the most common fractures in osteoporosis and are associated with increased morbidity, mortality, and costs. A subset of VFxs manifest clinically, usually with a sudden onset of severe back pain. Romosozumab is a monoclonal antibody that binds and...

Full description

Bibliographic Details
Main Authors: Piet Geusens, Mary Oates, Akimitsu Miyauchi, Jonathan D Adachi, Marise Lazaretti‐Castro, Peter R Ebeling, Carlos Augusto Perez Niño, Cassandra E Milmont, Andreas Grauer, Cesar Libanati
Format: Article
Language:English
Published: Wiley 2019-10-01
Series:JBMR Plus
Subjects:
ANABOLICS
CLINICAL TRIALS
FRACTURE RISK ASSESSMENT
FRACTURE PREVENTION
OSTEOPOROSIS
Online Access:https://doi.org/10.1002/jbm4.10211

Internet

https://doi.org/10.1002/jbm4.10211

Similar Items